KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Liabilities and Shareholders Equity (2016 - 2026)

Teva Pharmaceutical Industries filings provide 18 years of Liabilities and Shareholders Equity readings, the most recent being $40.0 billion for Q1 2026.

  • On a quarterly basis, Liabilities and Shareholders Equity rose 4.23% to $40.0 billion in Q1 2026 year-over-year; TTM through Mar 2026 was $160.8 billion, a 0.04% change, with the full-year FY2025 number at $40.7 billion, up 3.62% from a year prior.
  • Liabilities and Shareholders Equity hit $40.0 billion in Q1 2026 for Teva Pharmaceutical Industries, down from $40.7 billion in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $47.1 billion in Q1 2022 to a low of $38.4 billion in Q1 2025.
  • Median Liabilities and Shareholders Equity over the past 5 years was $42.1 billion (2023), compared with a mean of $42.2 billion.
  • Biggest five-year swings in Liabilities and Shareholders Equity: decreased 10.19% in 2025 and later increased 4.23% in 2026.
  • Teva Pharmaceutical Industries' Liabilities and Shareholders Equity stood at $44.0 billion in 2022, then decreased by 1.21% to $43.5 billion in 2023, then decreased by 9.55% to $39.3 billion in 2024, then grew by 3.62% to $40.7 billion in 2025, then fell by 1.74% to $40.0 billion in 2026.
  • The last three reported values for Liabilities and Shareholders Equity were $40.0 billion (Q1 2026), $40.7 billion (Q4 2025), and $39.9 billion (Q3 2025) per Business Quant data.